Investigation of Des-Arginin(9)-Bradykinin, Angiotensin II and mtDNA in patients with COVID-19 as a biomarker for the time-course of the disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030005

Enrollment

Registered

2022-12-06

Start date

2020-11-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Blood withdrawal is performed for 3 times (within 24h after admission, 24h and 72h thereafter, respectively) in patients with COVID-19 treated at the intensive care unit. Group 2: Blood withd

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - positive SARS-CoV-2 PCR test - treatment on intensive care unit

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Concentration of Des-Arg(9)-Bradykinin, Angiotensin II und mtDNA 72h after study inclusion.	—

Secondary

Measure	Time frame
Hospital Mortality ROTEM-Analysis Multiplate-Analysis Murray-Score for ARDS SOFA-Score ECMO-Therapy CRP PCT Lymphocytes GOT GPT LDH D-Dimers Fibrinogen	—

Countries

Germany

Contacts

Public ContactMichael Sander

Klinik für Anästhesiologie und operative Intensivmedizin

michael.sander@chiru.med.uni-giessen.de0641-98544401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026